Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2

Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2

US Patent 8444978 · Granted May 21, 2013

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Antibodies having specificity for CD38 and uses thereof2025
Antibodies against human CD39 and use thereof for inhibiting T regulatory cells 2023
Ex vivo generation of MHCII restricted CD4+ FOXP3+ regulatory T cells and therap2022
Ex vivo generation of γδ Foxp3+ regulatory T cells and therapeutic uses thereof2021
Monoclonal antibodies binding to the CD160 transmembrane isoform2021
Antibodies against human CD39 and use thereof for inhibiting T regulatory cells 2020
Antagonists of IL-17 isoforms and their uses2019
Anti-CD160 specific antibodies for the treatment of eye disorders based on neoan2019
Antagonists of IL-17 isoforms and their uses2017
IL-17 antagonist antibodies2017
Anti-CD160 specific antibodies for the treatment of eye disorders based on neoan2015
Compositions containing antibodies for treating CD5+ HLA-DR+ B or T cell related2014